Fourth-quarter and full-year 2025 results | Adjusted diluted EPS | | | | --- | --- | --- | | Fourth quarter | $1.501 | ↑12% | | Full year | $5.152 | % ↑10 | | W orldwide sales | Organic* sales growth for underlying base business** | 5 Full-year 2026 guidance | | $11.5B | ↑3.8%3 | 6.5% to 7.5% | | Fourth quarter | | Organic sales growth | | $44.3B | ↑6.7%4 | $5.55 to $5.80 | | Full year | | Adjusted diluted EPS | Key business units | Fourth-quarter sales Expanding in the fast-growing pulsed field ablation (P ...

Core Insights - Exact Sciences Corp. is being acquired by Abbott Laboratories for approximately $21 billion, with Abbott offering $105 per share to Exact Sciences' shareholders [2][8] - The U.S. cancer screening and precision oncology diagnostics market is valued at around $60 billion, with Exact Sciences reporting $851 million in revenue for Q3 and raising its full-year revenue forecast to between $3.22 billion and $3.235 billion [3][8] Company Overview - Exact Sciences specializes in cancer screening products, including Cologuard, and is expected to generate about $3 billion in revenue this year [8] - The company's shares rose 17% to just under $101, marking a significant increase of roughly 80% since the beginning of 2025 [9] Industry Context - The global cancer screening market was estimated to be worth over $100 billion last year, projected to grow at an annual rate of 6% to 8% due to increasing cancer diagnoses [6] - Approximately 2 million people in the U.S. and 20 million globally are diagnosed with cancer each year, driving demand for innovative cancer screening solutions [6]